Piśmiennictwo

  1. Rutkowski P. (red.). Złośliwe nowotwory skóry. Via Medica Gdańsk 2011.
  2. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W. Nowotwory złośliwe w Polsce w 2009 roku. Centrum Onkologii-Instytut 2011.
  3. Ruka W, Krzakowski M, Placek W, Rutkowski P, Nowecki ZI, Fijuth J, Nasierowska-Guttmejer A, Jeziorski A, Rudnicka L, Murawa P, Słuszniak J, Potemski P, Zaucha R, Wysocki PJ, Polkowski W, Kamińska-Winciorek G, Bajcar , Wojciech Biernat, Edward Towpik. Czerniaki skóry - zasady postępowania diagnostyczno-terapeutycznego. Onkologia w praktyce klinicznej 2009; 5, s. 20-32.
  4. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G, and on behalf of the ESMO Guidelines Working Group. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (suppl 7): vii86-vii91.
  5. NCCN Guidelines. Melanoma version 1.2013.
  6. Balch CM, Gershenwald JE, Soong SJ i wsp. Final version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 2009; 27: 6199-206.
  7. Morton DL, Thompson JF, Ochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Rentgen DS, Coventry BJ, Glass EC, Wang HJ. Sentinel-node biopsy or nodal observation in melanoma. NEJM 2006; 355: 1307-1317.
  8. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, Cormier JN, Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH; American Society of Clinical Oncology; Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012 Aug 10;30(23):2912-8. Epub 2012 Jul 9. Review.
  9. Nowecki ZI, Rutkowski P, Michej W. The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2–pT3). Ann Surg Oncol 2008; 15(8): 2223–2234.
  10. van Akkooi ACJ, Nowecki ZI, Voit C, Schaefer-Hesterberg G, Michej W, de Wilt JHW, Rutkowski P, Verhoef C, Eggermont AMM. Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients: A Multicenter Study in 388 Patients With Positive Sentinel Nodes. Ann Surg 2008; 248: 949-955.
  11. Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AM. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 2009 Aug;20 Suppl 6:vi22-9.
  12. Eggermont AMM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Sem Oncol 2007; 34: 509-515.
  13. Sondak VK, Gonzalez RJ, Kudchadkar R. Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am 2011; 20: 105-114.
  14. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012 Jan;48(2):218-25. Epub 2011 Nov 5.
  15. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012 Jun;13(6):589-97. Epub 2012 May 9.
  16. Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: rationale and Indications. Oncology 2004; 18: 99–107
  17. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. NEJM 2010; 19;363(8):711-23.
  18. Świtaj T, Wysocki P, Wojtukiewicz M, Potemski P, Rudnicka L, Bartnik W, Zgliczyński W, Zdanowski P, Kalinka-Warzocha E, Chmielowska E, Ziobro M, Poborski W, Filipczyk-Cisarż E, Zaucha R, Rogowski W, Falkowski S, Drosik K, Słowińska M, Siemiątkowski M, Szkatuła M, Ścibiorski C, Mackiewicz A, Rutkowski P. Ipilimumab – postęp w terapii chorych na zaawansowanego czerniaka. Onkol Prakt Klin 2011; 7: 231-245.
  19. Wolchok J.D., Hoos A., O’Day S.J. i wsp. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 2009; 15: 7412–7420.
  20. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun 5.
  21. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin A-M, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. Epub 2012 Jun 25
  22. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov L, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JMG, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin A-M, Patel K, Schadendorf D for the METRIC Study Group. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. Epub 2012 Jun 4
  23. Ascierto PA, Berking C, Agarwala SS et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 2012; 30 (Suppl); Abstr 8511.
  24. Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29(21): 2904–2909.